A unified anti-mutant dosing strategy

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 434-436

  Zhao, Xilin ^a   Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

MPC; Mutant selection window; PK PD indices

Indexed keywords

BETA LACTAM ANTIBIOTIC; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; DRUG DOSE REGIMEN; ERADICATION THERAPY; HUMAN; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION;

EID: 49649114861     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn229     Document Type: Article

References (31)

1. Klevens R, Morrison M, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc 2007; 298: 1763-71.
2. Zetola N, Francis J, Nuermberger E et al. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5: 275-86.
3. Goldstein F, Garau J. 30 years of penicillin-resistant S. pneumoniae myth or reality? Lancet 1997; 350: 233-4.
4. Dunbar L, Wunderink R, Habib M et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003; 37: 752-60.
5. Fox W, Elklard G, Mitchison D. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-79.
6. Stratton C. Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9: 10-6.
7. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Ambrose P, ed. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker, 2002; 1-22.
8. Cui J, Liu Y, Wang R et al. The mutant selection window demonstrated in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194: 1601-8.
9. Lipsitch M, Levin B. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-73.
10. Gumbo T, Louie A, Deziel M et al. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49: 3178-81.
11. Liu Y, Cui J, Wang R et al. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: Concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 2005; 56: 1172-5.
12. Dong Y, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1756-8.
13. Quinn B, Hussain S, Malik M et al. Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 2007; 60: 1380-3.
14. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: Measurement and potential uses of the mutant selection window. J Infect Dis 2002; 185: 561-5.
15. Firsov A, Smirnova M, Lubenko I et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58: 1185-92.
16. Rodriguez J, Cebrian L, Lopez M et al. Mutant prevention concentration: Comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53: 441-4.
17. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-7.
18. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112 275-85.
19. Marcusson L, Olofsson S, Lindgren P et al. Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 2005; 55: 938-43.
20. Drlica K, Zhao X, Blondeau J et al. Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob Agents Chemother 2006; 50: 403-4.
21. Tam V, Louie A, Deziel M et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007; 51: 744-7.
22. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002; 46: 522-4.
23. Drlica K, Zhao X, Wang JY et al. An anti-mutant approach for antimicrobial use. In: Fong I, Drlica K, eds. Antimicrobial Resistance and Implications for the 21st Century. New York City: Springer, 2008; 371-400.
24. Bast D, Low D, Duncan C et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux on levels of resistance. Antimicrob Agents Chemother 2000; 44: 3049-54.
25. Hansen G, Zhao X, Drlica K et al. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 120-4.
26. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 Suppl 3: S147-56.
27. Olofsson S, Marcusson L, Komp-Lindgren P et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: Relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57: 1116-21.
28. Rybak MJ. Pharmacodynamics: Relation to antimicrobial resistance. Am J Infect Control 2006; 34 Suppl 1: S28-45.
29. Blondeau J, Zhao X, Hansen G et al. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-8.
30. Metzler K, Hansen G, Hedlin P et al. Comparison of minimal inhibitory and mutant prevention concentrations of 4 fluoroquinolones: methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24: 161-7.
31. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-8.